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Abstract
Background: a-Enolase (ENO1) is a key glycolytic enzyme implicated in the development of many human cancers
including breast cancer. Increased expression of ENO1 has recently been reported in estrogen (ER)-positive human
breast cancer patients. The present study examined the expression of ENO1 and assessed its significance in canine
mammary carcinoma.
Results: Immunohistochemical staining was employed to investigate the expression of ENO1 in 82 cases of canine
mammary tumor (32 benign tumors and 50 carcinomas). Quantification of immunohistochemistry was carried out
using Quick score and the results showed cytoplasmic ENO1 overexpression in 9 of the 50 carcinomas (18%).
Overexpression of ENO1 correlated significantly with shorter cause-specific survival (P = 0.019), but was not
associated with ER positivity in canine mammary carcinoma.
Conclusions: Our findings suggest that overexpression of ENO1 may be used as a prognostic marker for poor
outcome in canine mammary carcinoma.
Background
Canine mammary tumor is one of the most common neo-
plasms in female dogs. Similar to human breast cancer,
canine mammary tumor is spontaneous, and the predomi-
nant malignant histological type is carcinoma [1-3].
Previous studies have shown that estrogen and progester-
one receptors (ER/PR), and epidermal growth factor recep-
tor 2 (HER2) are expressed in canine mammary carcinoma
with clinical implications similar to those in human [4-7].
It has been proposed that canine mammary carcinomas
may be a suitable model for comparative oncology studies
[4,5,7-9].
a-Enolase (ENO1) is a glycolytic enzyme that converts
2-phosphoglycerate into phosphoenolpyruvate in glyco-
lysis and a multifunctional protein that play a crucial
role in a variety of biological and pathophysiological
processes [10]. ENO1 may act as a stress protein that
promotes hypoxic tolerance in tumor cells by increasing
anaerobic metabolism [11]. ENO1 may also function as
a plasminogen receptor on the surface of a variety of
hematopoetic, epithelial and endothelial cells [12-17].
Recently, many lines of evidence suggested that ENO1
might contribute to tumor malignancy [17-26]. Upregu-
lation of ENO1 gene has been observed in several highly
tumorigenic or metastatic cell lines [21,23,24] and enzy-
matic activities in breast cancer concluded a role of
ENO1 in tumor progression [20]. A bioinformatics
study using gene chips and ESTs databases further sup-
ports a correlation between ENO1 expression and
tumorigenicity [18]. Increased cell-surface expression of
ENO1 promotes cell transformation and invasion in
non-small cell lung cancer and cancer of head and neck
[19,22]. The expression of ENO1 has been also reported
in pancreatic carcinoma [26] and hepatitis C virus-
related hepatocellular carcinoma [25]. More recently,
higher ENO1 expression was detected in ER+ breast
cancer patients compared to ER- patients [27]. Patients
with high ENO1 expression also had a poor prognosis
with greater tumor size, poor nodal status, and a shorter
disease-free survival [27].
Given the epidemiological and pathological similarity
between canine mammary carcinoma and human breast
cancer, and that canine mammary carcinoma may be a
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and the development of treatment, the present study exam-
ined the expression of ENO1 and assessed its clinical
significance in canine mammary carcinoma.
Results
The mean age when tumors were first identified was
11.2 ± 2.9 years (range 4-18 years). The mean maximum
tumor diameter was 3.8 ± 2.9 cm (range 0.2-14 cm). Of
the 82 dogs, 20 had undergone ovariohysterectomy
before presentation for surgical excision of the primary
tumor(s). 32 cases (39%) were benign tumors and
50 cases (61%) were histologically confirmed as mam-
mary carcinoma.
Immunohistochemical analyses revealed that mammary
carcinomas have higher expression of ENO1 as compared
to benign tumors (Figure 1 and Table 1). Overexpression
of ENO1 (as defined by a Quick score of 12 or greater)
was only identified in 18% (9/50) of dogs with mammary
carcinoma and none in the benign tumors. Moreover,
ENO1 overexpression occurred preferentially in the
tumor cells and not the adjacent non-tumor cells in
mammary carcinoma (Figure 2 and Table 2, P = 0.011).
The overexpression of ENO1 was not statistically asso-
ciated with clinicopathologic features such as age, ovario-
hysterectomy, size and grade of tumor, histological
classification, location of affected glands, and expression
of ER, PR, and HER2. We employed the same Quick
score system to quantify ER expression, although not sta-
tistically significant, a trend toward positive correlation
between high expression of ER (score of ≧12) and ENO1
overexpression was found (P = 0.063, Table 3). Kaplan
Meier survival analysis showed that cytoplasmic overex-
pression of ENO1 correlated significantly with shorter
5-year cause-specific survival in canine mammary carci-
noma (P = 0.019, Figure 3). Because age is strongly
related to death, control of the effect of age was accom-
plished by adding the mean age as a covariate to the mul-
tivariate survival analysis. The results of the age-adjusted
Cox regression model showed that ENO1 overexpression
retained statistical significance on cause-specific survival
(P = 0.044, Table 4).
Discussion
Breast cancer comparative oncology that integrates the
study of canine mammary carcinoma into studies of
human breast carcinoma may be uniquely positioned to
take advantage of the epidemiological and clinicopatho-
logic similarities between the two cancers of different
species to improve our understanding of breast cancer
biology and therapy.
Enhanced expression of ENO1 has been implicated in
human tumorigenesis and also used as a diagnostic marker
for human lung cancer [19,23,28-31]. ENO1 overexpres-
sion was also preferentially identified in human ER-posi-
tive breast cancer [27]. In this study, we investigated the
expression and clinical relevance of ENO1 in canine mam-
mary carcinoma. Immunohistochemical analysis revealed
that overexpression of ENO1 was only detected in tumor
cells of canine mammary carcinoma and significantly cor-
related with shorter 5-year cause-specific survival. The
results of the age-adjusted Cox regression analysis further
indicated that ENO1 overexpression was significantly and
independently associated with shorter cause-specific survi-
val. Unlike results from human breast cancer study, our
findings suggested that ER positivity was not associated
with ENO1 overexpression in canine mammary carci-
noma. Although quantification of ER expression with the
same Quick score system used for ENO1 revealed a trend
Figure 1 Representative figures of the immunohistochamical staining of ENO1 in (A) canine mammary carcinoma (Quick score = 12)
and (B) benign tumor (Quick score = 0). Carcinoma cells showed strong cytoplasmic staining of ENO1 (400×).
Table 1 Immunohistochemical semiquantitation of ENO1
expression with the Quick score in canine mammary
tumor
Histological classification Quick score
0-3 4-6 8-10 12+ total
Benign tumor 17 13 2 0 32
Carcinoma 15 15 11 9 50
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and ENO1 (P = 0.063). Further investigation is required to
elucidate whether the molecular events that underlie
ENO1 overexpression in canine mammary carcinoma is
ER signaling machinery-associated or -dependent as pro-
posed in human breast cancer [27].
The limitations of this study are primarily related to the
limited number of cases and its design as a retrospective
study which may make collecting complete clinical infor-
mation difficult. The finding of ENO1 overexpression in
the neoplastic tissue of canine mammary carcinoma and
its possible role in the prognosis of this disease is clinically
relevant, as ENO1 expression could be widely determined
on routinely processed, paraffin-embedded tissues. More-
over, agents with ENO1 attenuation activity might provide
an effective strategy for the treatment of breast cancer for
both dogs and human and merit further investigation.
Conclusions
Overexpression of ENO1 occurs in the neoplastic tissue
of a subset of dogs with canine mammary carcinoma. The ENO1 overexpression may be used as a marker for
poor outcome in this disease.
Methods
Patient Samples
Formalin-fixed, paraffin-embedded, surgically resected tis-
sue of canine mammary tumor diagnosed between January
2003 and April 2008 were retrieved from the archives of
the School of Veterinary Medicine, National Taiwan Uni-
versity, Taiwan. A cohort of eighty-two dogs including
twenty-one Maltese, ten Yorkshire terriers, nine Shih-
Tzus, seven Pomeranians, two Cocker spaniels, two
French spaniels, two Bichon Frisé, one poodle, one Ger-
man shepherd dog, one Shiba, one Beagle, one Labrador
Retriever and twenty-four mongrels with canine mammary
Figure 2 ENO1 overexpression identified in tumor cells (blue
arrow) and not adjacent non-tumor cells (red arrow) in a
representative canine mammary carcinoma (400×).
Table 2 Overexpression of ENO1 in canine mammary
tumor
ENO1 expression Benign
tumor
Carcinoma Total P
Tumor part
Quick
score
< 12 32(43.8%) 41(56.2%) 73 0.011
≧12 0 9(100%) 9
Non-tumor part
Quick
score
< 12 32(39.0%) 50(61.0%) 82 N/A
≧12 0 0 0
ENO1 overexpression is defined as a Quick score of ≧12
Table 3 Clinicopathologic characteristics of canine
mammary carcinoma
Quick score N P
<1 2 ≧12
Age
< 11 years 13(81.3) 3(18.7) 16 1.000
≧11 years 27(81.8) 6(18.2) 33
Ovariohysterectomy
No 31(83.8) 6(16.2) 37 0.580
Yes 10(76.9) 3(23.1) 13
Tumor Size
T1 (< 3 cm) 15(93.8) 1(6.2) 16 0.298
T2 (3-5 cm) 13(72.2) 5(27.8) 18
T3 (> 5 cm) 11(84.6) 2(15.4) 13
Grade
I 13(92.9) 1(7.1) 14 0.199
II/III 27(77.1) 8(22.9) 35
Histological classification
Carcinoma in benign tumor 4(80.0) 1(20.0) 5 0.566
Complex carcinoma 17(89.5) 2(10.5) 19
Simple carcinoma 20(76.9) 6(23.1) 26
Location of affected gland
cranial 13(76.5) 4(23.5) 17 0.566
caudal 25(83.3) 5(16.7) 30
ER
Negative 22(81.5) 5(18.5) 27 1.000
Positive 19(82.6) 4(17.4) 23
PR
Negative 2(100.0) 0(0.0) 2 1.000
Positive 39(81.3) 9(18.7) 48
HER2 Overexpression
Negative 35(83.3) 7(16.7) 42 0.574
Positive 6(75.0) 2(25.0) 8
ER with Quick score
< 12 38(86.4) 6(13.6) 44 0.063
≧12 3(50.0) 3(50.0) 6
1Tumor size measures maximum diameter
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Page 3 of 6tumor were analyzed in this study. Archived hematoxylin
and eosin (HE) sections from samples fixed in 10% buf-
fered formalin and embedded in paraffin wax were
reviewed to assess the diagnoses. The tumors were diag-
nosed according to the World Health Organization
(WHO) Histological Classification of Mammary Tumors
of the Dog and the Cat [32]. Tumor size was classified
according to the WHO Clinical Staging System TNM as
T1 (< 3 cm maximum diameter), T2 (3-5 cm maximum
diameter) and T3 (> 5 cm maximum diameter) [33]. The
largest one was used as the basis for classification in cases
of more than one tumor. Histological grading was per-
formed on HE-stained sections and graded by a scheme
based on tubule formation, nuclear pleomorphism, and
mitotic counts [34,35]. Each feature was scored 1 to 3
points. The scores were then added to obtain the tumor
grade. Final scores of 3-5 points, well-differentiated, were
designated grade I; scores of 6 and 7 points, moderately
differentiated carcinoma, were designated grade II; and
scores of 8 and 9 points, poorly differentiated carcinoma,
were designated grade III.
Immunoblotting
To detect endogenous the ENO1 protein and examine
antibody specificity, canine mammary carcinoma cell
line CF41 (ATCC, Rockville, MD, USA) was lysed in
PBS/TDS lysis buffer (10 mM Na2HPO4/150 mM NaCl/
1% Triton X-100/0.5% sodium deoxycholate/0.1% SDS/
10 mM NaF, pH 7.25) containing the protease inhibitor
cocktail (Calbiochem, San Diego, CA). The protein con-
centrations of the lysates were determined using the
BCA protein assay kit (Pierce, Rockford, IL). The lysates
were resolved in a 10% SDS-containing polyacrylamide
gel, blotted on a nitrocellulose membrane, and probed
with anti-ENO1 antibody (clone 8G8, Abnova Co., Tai-
pei, Taiwan) in 1:2000 dilution, or with pre-immunized
mouse total IgG. The immunocomplex was detected by
the goat anti-mouse IgG antibody conjugated with
horseradish peroxidase (Jackson ImmunoResearch Labs,
West Grove, PA) and visualized by SuperSignal chemilu-
minescence (Pierce, Rockford, IL). b-Actin (Sigma, St.
Louis, MO) was the loading control.
Immunohistochemistry
Paraffin-embedded canine mammary tumor tissue sec-
tions (4-μm) on poly-1-lysine-coated slides were first de-
waxed in xylene and re-hydrated through graded alco-
hols, followed by a rinse using 10 mM Tris-HCl (pH 7.4)
and 150 mM sodium chloride, then treated with 3%
hydrogen peroxide for 5 min. Slides were incubated with
1:2000 dilution of anti-ENO1 antibody for 1 hour at
room temperature, then thoroughly washed three times
with PBS. Bound antibodies were detected using the
LSAB+ kit (DAKO, Carpinteria, CA). The slides were
then counterstained with Gill Hematoxylin Solution II
(MERCK, Darmstadt, Germany). Paraffin-embedded sec-
tions of human breast cancer cells of homogeneous
ENO1 immunophenotype were included as positive con-
trols. Negative controls had the primary antibody omitted
and replaced by pre-immunized mouse total IgG. Quanti-
fication of immunohistochemistry was carried out using
Quick score which multiply the staining intensity by the
percentage of positive cells [36-38]. The intensity of
staining was scored as 0, 1, 2, and 3 standing for negative,
weak, moderate, and strong staining, respectively. The
percentage of tumor cells staining positively was scored
as follows: 0 = 0%, 1 = 1-20%, 2 = 21-40%, 3 = 41-60%,
4 = 61-80, and 5 = 81-100%, compared with the total of
tumor cells.
Immunohistochemistry was also performed in parallel
as described above with mouse monoclonal antibodies
for ER (clone 1D5, 1:35 dilution, Dako, Denmark), PR
(clone SP2, 1:200 dilution, Thermo Scientific, Fremont,
CA), and HER2 (A0485, 1:400 dilution, Dako, Denmark).
ER and PR immunoreactivity was considered positive
when more than 10% of the neoplastic cells expressed
this marker [4]. The American Society of Clinical
Oncology/College of American Pathologists guidelines
were used to evaluate HER2 expression (0 = no staining
Figure 3 Kaplan-Meier curves for cause-specific survival of
canine mammary carcinoma patients with and without ENO1
overexpression. Sixteen of the fifty cases lacked survival data and
were excluded from the analysis.
Table 4 Overexpression of ENO1 and age in the Cox
regression model for predicting Cause-specific survival
Variable Hazard ratio (95% CI) P
ENO1 overexpression 2.71 (1.03-7.15) 0.044
Age (11 y.o.) 1.42 (0.57-3.58) 0.456
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1+ = faint, barely perceptible membrane staining in
more than 10% of tumor cells; 2+ = weak to moderate
complete membrane staining observed in more than
10% of tumor cells or strong complete membrane stain-
ing in less than 30% of tumor cells; 3+ = strong and
complete membrane staining in more than 30% tumor
c e l l s ) [ 3 9 ] .I nt h i ss t u d y ,o v e r e x p r e s s i o no fH E R 2w a s
defined as a score of 3+.
Histological grading and immunohistochemical results
were evaluated by two investigators (veterinary patholo-
gists) scoring independently. Conflicting scores were
resolved at a double-headed microscope.
Statistical Analysis
Overexpression of ENO1 was defined as a Quick score of
12 or greater on the scale of 0 to 15. Patient data were
obtained from medical records. Correlations of ENO1
and clinicopathologic parameters of canine mammary
c a r c i n o m aw e r ee x a m i n e db yP e a r s o n ’s chi-square test.
Survival rate was calculated using Kaplan-Meier analysis
and compared by the Cochran-Mantel-Haenszel test
(log-rank test). Cox proportional hazards regression
model was used to control the effect of age on survival.
Cause-specific survival was defined as the time between
date of diagnosis and date of cancer-related death. Fol-
low-up was obtained by telephone call up to August
2010. If a patient had died, the information regarding the
cause of death was obtained by contact with the veteri-
narian. Subjects still alive at the end of the study were
censored at the date of last follow-up. Cases that lacked
survival data were excluded from the analysis. A P value
of less than 0.05 was considered to indicate statistical
significance.
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